US2913451A
(en)
*
|
1957-04-04 |
1959-11-17 |
Mallinckrodt Chemical Works |
Iodophenylamidoalkanesulfonic acid compounds
|
US5700444A
(en)
*
|
1992-02-20 |
1997-12-23 |
Rhomed Incorporated |
Chemotactic peptide pharmaceutical applications
|
US5759515A
(en)
*
|
1989-08-09 |
1998-06-02 |
Rhomed Incorporated |
Polyvalent peptide pharmaceutical applications
|
US5469854A
(en)
|
1989-12-22 |
1995-11-28 |
Imarx Pharmaceutical Corp. |
Methods of preparing gas-filled liposomes
|
US5773024A
(en)
*
|
1989-12-22 |
1998-06-30 |
Imarx Pharmaceutical Corp. |
Container with multi-phase composition for use in diagnostic and therapeutic applications
|
US6146657A
(en)
*
|
1989-12-22 |
2000-11-14 |
Imarx Pharmaceutical Corp. |
Gas-filled lipid spheres for use in diagnostic and therapeutic applications
|
US5305757A
(en)
*
|
1989-12-22 |
1994-04-26 |
Unger Evan C |
Gas filled liposomes and their use as ultrasonic contrast agents
|
US5585112A
(en)
*
|
1989-12-22 |
1996-12-17 |
Imarx Pharmaceutical Corp. |
Method of preparing gas and gaseous precursor-filled microspheres
|
US20020032313A1
(en)
|
1991-03-29 |
2002-03-14 |
Genentech, Inc. |
Vascular endothelial cell growth factor antagonists
|
OA10149A
(en)
*
|
1991-03-29 |
1996-12-18 |
Genentech Inc |
Vascular endothelial cell growth factor antagonists
|
US5205290A
(en)
*
|
1991-04-05 |
1993-04-27 |
Unger Evan C |
Low density microspheres and their use as contrast agents for computed tomography
|
US5861301A
(en)
*
|
1992-02-20 |
1999-01-19 |
American Cayanamid Company |
Recombinant kinase insert domain containing receptor and gene encoding same
|
US5965132A
(en)
*
|
1992-03-05 |
1999-10-12 |
Board Of Regents, The University Of Texas System |
Methods and compositions for targeting the vasculature of solid tumors
|
WO1993017715A1
(en)
|
1992-03-05 |
1993-09-16 |
Board Of Regents, The University Of Texas System |
Diagnostic and/or therapeutic agents, targeted to neovascular endothelial cells
|
WO1993022343A1
(en)
*
|
1992-05-01 |
1993-11-11 |
The Rockfeller University |
Multiple antigen peptide system having adjuvant properties and vaccines prepared therefrom
|
US6824777B1
(en)
*
|
1992-10-09 |
2004-11-30 |
Licentia Ltd. |
Flt4 (VEGFR-3) as a target for tumor imaging and anti-tumor therapy
|
HU221343B1
(en)
|
1992-10-28 |
2002-09-28 |
Genentech Inc |
Use of anti-vegf antibodies for the treatment of cancer
|
DE69434538T2
(en)
*
|
1994-03-08 |
2006-08-10 |
Human Genome Sciences, Inc. |
Vascular endothelial growth factor 2
|
US6221839B1
(en)
*
|
1994-11-14 |
2001-04-24 |
Helsinki University Licensing Ltd. Oy |
FIt4 ligand and methods of use
|
US6403088B1
(en)
*
|
1995-08-01 |
2002-06-11 |
Helsinki University Licensing, Ltd. |
Antibodies reactive with VEGF-C, a ligand for the Flt4 receptor tyrosine kinase (VEGFR-3)
|
US6245530B1
(en)
*
|
1995-08-01 |
2001-06-12 |
Ludwig Institute For Cancer Research |
Receptor ligand
|
US6645933B1
(en)
|
1995-08-01 |
2003-11-11 |
Helsinki University Licensing Ltd. Oy |
Receptor ligand VEGF-C
|
US6130071A
(en)
*
|
1997-02-05 |
2000-10-10 |
Helsinki University Licensing, Ltd. |
Vascular endothelial growth factor C (VEGF-C) ΔCys156 protein and gene, and uses thereof
|
JP4215820B2
(en)
|
1995-06-07 |
2009-01-28 |
イマアーレクス・フアーマシユーチカル・コーポレーシヨン |
Novel targeted compositions for diagnostic and therapeutic uses
|
US6033645A
(en)
*
|
1996-06-19 |
2000-03-07 |
Unger; Evan C. |
Methods for diagnostic imaging by regulating the administration rate of a contrast agent
|
US6231834B1
(en)
*
|
1995-06-07 |
2001-05-15 |
Imarx Pharmaceutical Corp. |
Methods for ultrasound imaging involving the use of a contrast agent and multiple images and processing of same
|
US6521211B1
(en)
*
|
1995-06-07 |
2003-02-18 |
Bristol-Myers Squibb Medical Imaging, Inc. |
Methods of imaging and treatment with targeted compositions
|
US7423125B2
(en)
*
|
1995-08-01 |
2008-09-09 |
Vegenics Limited |
Antibodies to VEGF-C
|
US6361946B1
(en)
*
|
1997-02-05 |
2002-03-26 |
Licentia Ltd |
Vascular endothelial growth factor C (VEGF-C) protein and gene, mutants thereof, and uses thereof
|
PT848755E
(en)
*
|
1995-09-08 |
2003-12-31 |
Genentech Inc |
PROTEIN RELATED TO VEGF
|
EP1007101B1
(en)
|
1996-10-28 |
2006-05-17 |
GE Healthcare AS |
Improvements in or relating to diagnostic/therapeutic agents
|
US6331289B1
(en)
*
|
1996-10-28 |
2001-12-18 |
Nycomed Imaging As |
Targeted diagnostic/therapeutic agents having more than one different vectors
|
US6261537B1
(en)
*
|
1996-10-28 |
2001-07-17 |
Nycomed Imaging As |
Diagnostic/therapeutic agents having microbubbles coupled to one or more vectors
|
CA2270120A1
(en)
*
|
1996-10-28 |
1998-05-07 |
Pal Rongved |
Improvements in or relating to diagnostic/therapeutic agents
|
GB9708265D0
(en)
*
|
1997-04-24 |
1997-06-18 |
Nycomed Imaging As |
Contrast agents
|
US7125714B2
(en)
*
|
1997-02-05 |
2006-10-24 |
Licentia Ltd. |
Progenitor cell materials and methods
|
US20020010137A1
(en)
*
|
1997-09-18 |
2002-01-24 |
Genentech, Inc. |
Methods and compositions for inhibiting neoplastic cell growth
|
US6245318B1
(en)
*
|
1997-05-27 |
2001-06-12 |
Mallinckrodt Inc. |
Selectively binding ultrasound contrast agents
|
ATE371727T1
(en)
*
|
1997-06-18 |
2007-09-15 |
Merck & Co Inc |
KDR, A HUMAN TYROSINE KINASE RECEPTOR
|
US6777534B1
(en)
*
|
1997-12-09 |
2004-08-17 |
Children's Medical Center Corporation |
Peptide antagonists of vascular endothelial growth factor
|
IL138214A0
(en)
*
|
1998-03-09 |
2001-10-31 |
Zealand Pharmaceuticals As |
Pharmacolgically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis
|
US6524553B2
(en)
*
|
1998-03-31 |
2003-02-25 |
Bristol-Myers Squibb Pharma Company |
Quinolone vitronectin receptor antagonist pharmaceuticals
|
BR9909420A
(en)
|
1998-03-31 |
2001-09-25 |
Du Pont Pharm Co |
Compound, kit, diagnostic or therapeutic metallopharmaceutical composition, ultrasound contrast agent composition, therapeutic radiopharmaceutical composition and diagnostic radiopharmaceutical composition
|
US6537520B1
(en)
*
|
1998-03-31 |
2003-03-25 |
Bristol-Myers Squibb Pharma Company |
Pharmaceuticals for the imaging of angiogenic disorders
|
US6548663B1
(en)
*
|
1998-03-31 |
2003-04-15 |
Bristol-Myers Squibb Pharma Company |
Benzodiazepine vitronectin receptor antagonist pharmaceuticals
|
US6548048B1
(en)
*
|
1998-04-28 |
2003-04-15 |
Amersham Health As |
Lipopeptide stabilized microbubbles as diagnostic/therapeutic agents
|
US20030236190A1
(en)
*
|
1998-09-02 |
2003-12-25 |
Renuka Pillutla |
Isulin and IGF-1 receptor agonists and antagonists
|
US6875741B2
(en)
*
|
1998-09-02 |
2005-04-05 |
Renuka Pillutla |
Insulin and IGF-1 receptor agonists and antagonists
|
US7173005B2
(en)
*
|
1998-09-02 |
2007-02-06 |
Antyra Inc. |
Insulin and IGF-1 receptor agonists and antagonists
|
DE19941092A1
(en)
|
1999-08-30 |
2001-03-01 |
Philips Corp Intellectual Pty |
Network with an identifier reduction
|
AU783683B2
(en)
*
|
2000-01-18 |
2005-11-24 |
Vegenics Limited |
VEGF-D/VEGF-C/VEGF peptidomimetic inhibitor
|
US7740841B1
(en)
*
|
2000-01-28 |
2010-06-22 |
Sunnybrook Health Science Center |
Therapeutic method for reducing angiogenesis
|
JP2003528824A
(en)
*
|
2000-02-04 |
2003-09-30 |
スプラテック ファーマ インコーポレイティド |
Ligand for vascular endothelial growth factor receptor
|
WO2001064235A1
(en)
*
|
2000-03-02 |
2001-09-07 |
Ludwig Institute For Cancer Research |
Methods for treating, screening for, and detecting cancers expressing vascular endothelial growth factor d
|
EP1519193B1
(en)
|
2000-03-02 |
2011-11-09 |
Vegenics Pty Ltd |
Methods for detecting cancers expressing vascular endothelial growth factor D
|
US20020102260A1
(en)
*
|
2000-03-02 |
2002-08-01 |
Marc Achen |
Methods for treating neoplastic disease characterized by vascular endothelial growth factor D expression, for screening for neoplastic disease or metastatic risk, and for maintaining vascularization of tissue
|
US20010031485A1
(en)
*
|
2000-03-22 |
2001-10-18 |
Sibtech, Inc. |
Recombinant proteins containing Shiga-like toxin and vascular endothelial growth factor fragments
|
JP2003528632A
(en)
*
|
2000-03-31 |
2003-09-30 |
インスティティ・パスツール |
Peptide inhibiting vascular endothelial growth factor (VEGF) -mediated angiogenesis, polynucleotide encoding the peptide and methods of use
|
AU6456501A
(en)
*
|
2000-05-03 |
2001-11-12 |
Ludwig Inst Cancer Res |
A method for activating only the vascular endothelial growth factor receptor-3 and uses thereof
|
EP1166798A1
(en)
|
2000-06-23 |
2002-01-02 |
Schering Aktiengesellschaft |
Combinations and compositions which interfere with VEGF/VEGF and angiopoietin/ Tie receptor function and their use
|
KR20030036238A
(en)
|
2000-06-23 |
2003-05-09 |
쉐링 악티엔게젤샤프트 |
Combinations and Compositions Which Interfere with VEGF/VEGF and Angiopoietin/Tie Receptor Function and Their Use (II)
|
EP1166799A1
(en)
|
2000-06-28 |
2002-01-02 |
Schering Aktiengesellschaft |
Combinations and compositions which interfere with VEGF/VEGF and angiopoietin/Tie receptor function and their use (II)
|
WO2002007747A1
(en)
*
|
2000-07-18 |
2002-01-31 |
Joslin Diabetes Center, Inc. |
Methods of modulating fibrosis
|
US20020091082A1
(en)
*
|
2000-09-13 |
2002-07-11 |
Aiello Lloyd P. |
Methods of modulating symptoms of hypertension
|
US20030082103A1
(en)
*
|
2000-10-11 |
2003-05-01 |
Targesome, Inc. |
Targeted therapeutic lipid constructs having cell surface targets
|
US20020091567A1
(en)
*
|
2001-01-09 |
2002-07-11 |
Royston Tymarshall E. |
System and method for electronically redeeming coupons
|
US7611711B2
(en)
*
|
2001-01-17 |
2009-11-03 |
Vegenics Limited |
VEGFR-3 inhibitor materials and methods
|
WO2002072011A2
(en)
*
|
2001-03-08 |
2002-09-19 |
Targesome, Inc. |
Stabilized therapeutic and imaging agents
|
WO2002083849A2
(en)
*
|
2001-04-13 |
2002-10-24 |
Human Genome Sciences, Inc. |
Vascular endothelial growth factor 2
|
EP1456240A4
(en)
*
|
2001-10-24 |
2006-08-09 |
Antyra Inc |
Target specific screening and its use for identifying target binders
|
US7211240B2
(en)
|
2002-03-01 |
2007-05-01 |
Bracco International B.V. |
Multivalent constructs for therapeutic and diagnostic applications
|
CA2477935C
(en)
*
|
2002-03-01 |
2015-01-06 |
Bracco International Bv |
Multivalent constructs for therapeutic and diagnostic applications
|
EP2301587B1
(en)
*
|
2002-03-01 |
2014-06-25 |
Dyax Corp. |
KDR and VEGF/KDR binding peptides and their use in diagnosis
|
WO2004065621A1
(en)
|
2002-03-01 |
2004-08-05 |
Dyax Corp. |
Kdr and vegf/kdr binding peptides and their use in diagnosis and therapy
|
US20040033949A1
(en)
*
|
2002-05-06 |
2004-02-19 |
Genentech, Inc. |
Use of VEGF for treating bone defects
|
US20040212193A1
(en)
|
2002-10-08 |
2004-10-28 |
Johnstone Ian David |
Connector
|
NO20026286D0
(en)
|
2002-12-30 |
2002-12-30 |
Amersham Health As |
New peptides
|
NO20026285D0
(en)
|
2002-12-30 |
2002-12-30 |
Amersham Health As |
New peptides
|
US7183256B2
(en)
*
|
2003-03-21 |
2007-02-27 |
Cleveland Clinic Foundation |
TIMP3 as VEGF inhibitor
|
US7601341B2
(en)
*
|
2003-06-05 |
2009-10-13 |
Research Development Foundation |
Vascular endothelial growth factor fusion constructs used to inhibit osteoclastogenesis
|
WO2005016963A2
(en)
|
2003-06-12 |
2005-02-24 |
Ludwig Institute For Cancer Research |
Heparin binding veger-3 ligands
|
US20050043235A1
(en)
|
2003-06-12 |
2005-02-24 |
Kari Alitalo |
Use of VEGF-C or VEGF-D in reconstructive surgery
|
JP2005110508A
(en)
|
2003-10-02 |
2005-04-28 |
Nec Soft Ltd |
Growth factor-like protein derived from snake venom having specific binding property to vascular endothelial growth factor receptor 2
|
EP1715897B2
(en)
|
2004-01-20 |
2013-10-30 |
Sunnybrook and Women's College Health Sciences Centre |
High frequency ultrasound imaging using contrast agents
|
US8067368B2
(en)
|
2004-01-27 |
2011-11-29 |
The Ohio State University Research Foundation |
Vascular endothelial growth factors and methods of their use
|
JP2008509157A
(en)
|
2004-08-06 |
2008-03-27 |
ソフェリオン セラピューティクス,インコーポレイテッド |
Anti-angiogenic peptides and methods of use thereof
|